HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for immuno-oncology and immune-related diseases, today announced it has selected ...

Most Favored Nation (MFN) drug pricing is just price controls by another name. Instead of openly capping what a drug can cost ...

FDA moves shaping drug development and oversight include new gene therapy guidance, clinical trial transparency efforts, and recent drug approvals.

Neuroscience trials require high-precision, sensitive endpoint measurements, yet sponsors often face challenges with ...

Wanted: a cheap, multipotent treatment for viral infections. Must be able to handle new or unfamiliar strains, or (even ...

Amazon's cloud unit on Tuesday launched Amazon Bio Discovery, an artificial intelligence application designed to speed ...

By Maggie Fick LONDON, April 14 (Reuters) - Danish drugmaker Novo Nordisk, which has fallen behind Eli Lilly in the immensely ...

A Luxembourg-based start-up has raised $10 million to help the pharmaceutical sector exploit the power of AI to drive faster ...

Biotech has reasserted itself over the past year as drug approvals, obesity and GLP-1 programs, oncology pipelines, and ...

For every life-changing new drug that comes to market, many candidates fail along the way. An artificial intelligence-based ...

In this Q&A, Jenna DiRito, PhD, COO and co-founder of Revalia Bio, discusses how earlier, human-relevant data is reshaping go ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...